RFA-CA-23-036: Mechanisms of Fusion-Driven Oncogenesis in Childhood Cancers (U01 Clinical Trial Not Allowed)
Closed
This grant is closed. Who won this program's grants before is below, and similar open grants are at the end of the page. It is in our archive of National Institutes of Health notices from 2023.
National Institutes of Health offered grants of up to $325,000 to nonprofits, colleges and universities, state and local governments, tribes, small businesses and businesses. Applications closed on November 15, 2023.
From the official notice on Grants.gov, last changed July 17, 2023. Checked November 7, 2026.
- Award ceiling$325,000
- Cost sharingNot required
- Funding typeCooperative Agreement
About this NIH notice
- Activity codeU01
- Clinical trialsNot allowed
- Funded byNCI
- Median yearly award$537,050
- Typical project length5 years
- U01, Research Project Cooperative Agreement. Like an R01, but NIH staff are substantially involved in the work. Other open U01 notices.
Projects funded under RFA-CA-23-036 were run by National Cancer Institute (NCI, 3 projects). Contact the program officer at the institute that fits your project before you apply; the notice lists them.
Application due dates, page limits and budget limits are set in the notice. Read RFA-CA-23-036 in the NIH Guide.
Key dates
| Posted | July 17, 2023 |
|---|---|
| Deadline | November 15, 2023 |
| Archived by Grants.gov | December 21, 2023 |
Who can apply
This opportunity was open to nonprofits, colleges and universities, state and local governments, tribes, small businesses and businesses.
All 15 applicant types the notice lists
- State governments
- County governments
- City or township governments
- Special district governments
- Independent school districts
- Public and State controlled institutions of higher education
- Native American tribal governments (Federally recognized)
- Public housing authorities/Indian housing authorities
- Native American tribal organizations (other than Federally recognized tribal governments)
- Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education
- Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education
- Private institutions of higher education
- For profit organizations other than small businesses
- Small businesses
- Others (see text field entitled "Additional Information on Eligibility" for clarification)
Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession; Non-domestic (non-U.S.) Entities (Foreign Institutions) are not eligible to apply. Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, are allowed.
Is this a realistic fit?
- Projects NIH funded under this notice had a median yearly award of $537,050; it allows up to $325,000 per award.
- Most of the program's money (69% over five years) went to colleges and universities.
- No cost sharing or match is required.
What the grant funds
NCI is forming the Targeting Fusion Oncoproteins in Childhood Cancers (TFCC) Network to advance our understanding of the mechanisms of action of fusion oncoproteins in pediatric cancers and to apply novel chemical strategies for developing targeted therapeutic approaches. This RFA will use the U01 mechanism to solicit applications focused on molecular mechanisms by which fusion oncoproteins drive pediatric cancers with the goals of better understanding the biology of these cancers and identifying potential drug targets or critical dependencies. Examples of relevant research activities include, but are not limited to, dissecting pathways by which these fusion oncoproteins cause cancer, characterizing the composition and structure of fusion oncoprotein complexes, and delineating the roles of ncRNAs and post-translational modifications in fusion oncoprotein function. Funding priority will be given to applications that focus on fusion oncoproteins found in tumors that have high risk of treatment failure and for which there has been little progress in identifying targeted agents. Applications focused on pediatric solid tumors and brain tumors are particularly encouraged. U01 recipients will meet regularly with UM1 grantees funded through the Next Generation Chemistry Centers for Fusion Oncoproteins FOA.
Funded under RFA-CA-23-036 so far
NIH funded 3 projects under RFA-CA-23-036 in fiscal 2024 to 2026, at 3 institutions. The median yearly award was $537,050.
| Project | Institution | Fiscal year | Award |
|---|---|---|---|
| Discovering the mechanisms underlying oncogenesis by ZFTA-RELA and pinpointing therapeutic targets. | St. Jude Children's Research Hospital | 2026 | $538,937 |
| Overcoming Limitations of BETInhibition in NUT Carcinoma | Brigham and Women's Hospital | 2026 | $532,606 |
| Desmoplastic small round cell tumor: harnessing new insights and new models | Sloan-Kettering Inst Can Research | 2026 | $185,756 |
Who has won Cancer Biology Research grants before
From fiscal 2021 to 2025, Cancer Biology Research (93.396) awarded $4.3 billion across 3,142 grant awards, an average of $1.4 million per award.
| Recipient | State | Awards | Amount |
|---|---|---|---|
| The Trustees of Columbia University in the City of New York | New York | 70 | $151 million |
| The Univeristy of Texas M.D. Anderson Cancer Center | Texas | 109 | $144 million |
| Sloan-Kettering Institute for Cancer Research | New York | 66 | $136 million |
| Dana-Farber Cancer Institute, Inc. | Massachusetts | 47 | $107 million |
| The Regents of the University of California, San Francisco | California | 64 | $95.5 million |
Applying now
This notice no longer takes applications. Agencies often post the same opportunity again under a new number, so check the program's notices on Grants.gov and the similar open grants below.
The notice on Grants.gov keeps its full text and attachments, which is useful for planning a resubmission.
Questions people ask
Is RFA-CA-23-036 still open?
No. It closed on November 15, 2023.
Who can apply for Mechanisms of Fusion-Driven Oncogenesis in Childhood Cancers (U01 Clinical Trial Not Allowed)?
National Institutes of Health accepted applications from nonprofits, colleges and universities, state and local governments, tribes, small businesses and businesses. The notice adds further conditions, so read its eligibility section.
What is the deadline for Mechanisms of Fusion-Driven Oncogenesis in Childhood Cancers (U01 Clinical Trial Not Allowed)?
Closed November 15, 2023. Applications are no longer accepted; the program's newer notices are on this page when there are any.
How much funding is available?
Awards of up to $325,000 each.
Who has been funded under RFA-CA-23-036?
NIH RePORTER lists 3 projects funded under RFA-CA-23-036 in fiscal 2024 to 2026, at 3 institutions. The most were at St. Jude Children's Research Hospital, Brigham and Women's Hospital, Sloan-Kettering Inst Can Research.
Who has won Cancer Biology Research grants before?
The largest recipients over five fiscal years were The Trustees of Columbia University in the City of New York, The Univeristy of Texas M.D. Anderson Cancer Center, Sloan-Kettering Institute for Cancer Research. The program made 3,142 awards worth $4.3 billion in that time.
Similar open grants
- Single Source for the Continuation of the Caring for OutPatiEnts after Acute Kidney Injury (COPE-AKI) Scientific and Data Research Center (U01 Clinical Trial Required)
- Single Source for the Continuation of the Epidemiology of Diabetes Interventions and Complications (EDIC) Study Research Center (Collaborative U01 Clinical Trial Not Allowed)
- Amyotrophic Lateral Sclerosis (ALS) Intermediate Patient Population Expanded Access (U01 Clinical Trial Required)
- Single Source for the Continuation of the Physiology of the Weight Reduced State (POWERS) Study (U01- Clinical Trials Required)
- Canine Cancer Immunotherapy Network (K9CIN; U01 Clinical Trial Not Allowed)
- Opportunities for Collaborative Research with the NIH Intramural Research Program (U01 Clinical Trial Optional)